Nodal Epstein-Barr virus-positive T/NK-cell lymphoma (EB-nTNKL) is a rare and clinically aggressive malignancy for which standardized treatments remain undefined. A case study published in Internal Medicine reports on a young male patient diagnosed with EB-nTNKL whose disease progressed despite initial chemotherapy, including regimens containing L-asparaginase.
In this case, myeloablative allogeneic hematopoietic stem cell transplantation (alloHSCT) was performed using an available donor, even though the initial chemotherapy showed poor efficacy. Post-transplantation, the patient achieved sustained remission and long-term disease-free survival.
The findings suggest that prompt alloHSCT may be a critical intervention in managing this rare lymphoma, especially when conventional chemotherapy regimens are ineffective. While the report is limited to a single case, it contributes to the sparse body of literature available on EB-nTNKL and supports further investigation into the timing and utility of stem cell transplantation in similar clinical scenarios.
The study highlights the many challenges of treating EB-nTNKL and illustrates how early access to stem cell transplantation might improve outcomes in select patients.
